Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald Richards

Showing results (11-20 of 33) with videos related to

Pageof 4
Sort By:
Breast Cancer Research and Treatment|January 11, 2016
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancerJoanne L Blum, Anthony Gonçalves, Noa Efrat, et al.
Clinical Colorectal Cancer|November 28, 2008
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancerThomas Cartwright, Paul Kuefler, Allen Cohn, et al.
Targeted Oncology|October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Targeted Oncology|April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Clinical Colorectal Cancer|August 23, 2011
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancerAllen L Cohn, Grace C Shumaker, Pankaj Khandelwal, et al.
JCO Precision Oncology|July 19, 2023
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for CancersAlan H Bryce, David D Thiel, Michael V Seiden, et al.
International Journal of Cancer|January 10, 2018
Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancerScott Morris, Anil Vachani, Harvey I Pass, et al.
International Journal of Oncology|October 2, 2014
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancerAllen Cohn, Michael M Lahn, Kristen E Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast CancerAditya Bardia, Virginia Kaklamani, Sharon Wilks, et al.
The American Journal of Cardiology|December 21, 2022
Hemodynamic Gain Index and Exercise Capacity in Heart Failure With Preserved Ejection FractionVicente Morales-Oyarvide, Donald Richards, Nicholas S Hendren, et al.
Pageof 4

Showing results (11-20 of 33) with videos related to

Sort By:
Pageof 4
Breast Cancer Research and Treatment|January 11, 2016
A phase II trial of trabectedin in triple-negative and HER2-overexpressing metastatic breast cancerJoanne L Blum, Anthony Gonçalves, Noa Efrat, et al.
Clinical Colorectal Cancer|November 28, 2008
Results of a phase II trial of cetuximab plus capecitabine/irinotecan as first-line therapy for patients with advanced and/or metastatic colorectal cancerThomas Cartwright, Paul Kuefler, Allen Cohn, et al.
Targeted Oncology|October 27, 2020
Correction to: Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Targeted Oncology|April 22, 2020
Phase Ib Trial of the PI3K Inhibitor Copanlisib Combined with the Allosteric MEK Inhibitor Refametinib in Patients with Advanced CancerRamesh K Ramanathan, Daniel D Von Hoff, Ferry Eskens, et al.
Clinical Colorectal Cancer|August 23, 2011
An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancerAllen L Cohn, Grace C Shumaker, Pankaj Khandelwal, et al.
JCO Precision Oncology|July 19, 2023
Performance of a Cell-Free DNA-Based Multi-cancer Detection Test in Individuals Presenting With Symptoms Suspicious for CancersAlan H Bryce, David D Thiel, Michael V Seiden, et al.
International Journal of Cancer|January 10, 2018
Whole blood FPR1 mRNA expression predicts both non-small cell and small cell lung cancerScott Morris, Anil Vachani, Harvey I Pass, et al.
International Journal of Oncology|October 2, 2014
A phase I dose-escalation study to a predefined dose of a transforming growth factor-β1 monoclonal antibody (TβM1) in patients with metastatic cancerAllen Cohn, Michael M Lahn, Kristen E Williams, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2021
Phase I Study of Elacestrant (RAD1901), a Novel Selective Estrogen Receptor Degrader, in ER-Positive, HER2-Negative Advanced Breast CancerAditya Bardia, Virginia Kaklamani, Sharon Wilks, et al.
The American Journal of Cardiology|December 21, 2022
Hemodynamic Gain Index and Exercise Capacity in Heart Failure With Preserved Ejection FractionVicente Morales-Oyarvide, Donald Richards, Nicholas S Hendren, et al.
Pageof 4